C26 Stock Chart & Stats
€14.54
€1.26(10.29%)
At close: 4:00 PM EDT
€14.54
€1.26(10.29%)
Day’s Range― - ―
52-Week Range€10.64 - €17.06
Previous CloseN/A
Volume400.00
Average Volume (3M)40.00
Market Cap
€351.56M
Enterprise Value€3.13B
Total Cash (Recent Filing)€172.19M
Total Debt (Recent Filing)€52.27M
Price to Earnings (P/E)30.5
Beta0.73
Next Earnings
Oct 29, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)5.41
Shares Outstanding23,851,547
10 Day Avg. Volume6
30 Day Avg. Volume40
Financial Highlights & Ratios
PEG Ratio2.78
Price to Book (P/B)4.22
Price to Sales (P/S)4.94
P/FCF Ratio20.63
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.55
Revenue Forecast (FY)€69.87M
Bulls Say, Bears Say
Bulls Say
Strong And Consistent ProfitabilitySustained gross and EBIT margins indicate that CellaVision has a differentiated, profitable business model with meaningful operating quality. Maintaining these levels across periods supports reinvestment, resilience against moderate cost pressure, and durable earnings generation as the installed base expands.
Conservative Balance SheetVery low leverage gives CellaVision substantial financial flexibility to fund product development, commercial expansion, and strategic initiatives without relying heavily on external financing. The growing equity base and solid returns on equity also support balance-sheet resilience through changing demand conditions.
Americas Growth And Product ExpansionStrong Americas momentum, supported by instrument sales, tenders, and laboratory-network refreshes, demonstrates commercial traction in an important region. The Bone Marrow Aspirate launch adds a new growth avenue, potentially broadening the product platform and supporting growth beyond the current core offering.
Bears Say
Recent Revenue And Margin DecelerationThe decline in trailing revenue and profitability shows that recent performance has softened after a stronger 2025. If this persists, slower growth could reduce operating leverage, constrain the pace of earnings expansion, and make it harder for new products or regional recovery to offset weakness.
More Volatile Free Cash FlowAlthough operating cash flow has generally exceeded net income, the sharper decline and variability in free cash flow make cash conversion less dependable than reported profitability. Continued volatility could limit internally funded investment and increase sensitivity to working-capital movements during expansion.
Persistent APAC And China WeaknessWeak APAC performance, particularly in China, is a regional drag on consolidated growth and reduces the contribution from an important geographic market. Continued weakness could delay recovery in the region, pressure sales mix, and require stronger performance elsewhere to sustain overall expansion.
CellaVision AB News
C26 FAQ
What was CellaVision AB’s price range in the past 12 months?
CellaVision AB lowest stock price was €10.64 and its highest was €17.06 in the past 12 months.
What is CellaVision AB’s market cap?
CellaVision AB’s market cap is €351.56M.
When is CellaVision AB’s upcoming earnings report date?
CellaVision AB’s upcoming earnings report date is Oct 29, 2026 which is in 7 days.
How were CellaVision AB’s earnings last quarter?
CellaVision AB released its earnings results on Jul 17, 2026. The company reported €0.123 earnings per share for the quarter, beating the consensus estimate of €0.12 by €0.003.
Is CellaVision AB overvalued?
According to Wall Street analysts CellaVision AB’s price is currently Overvalued.
Does CellaVision AB pay dividends?
CellaVision AB does not currently pay dividends.
What is CellaVision AB’s EPS estimate?
CellaVision AB’s EPS estimate is 0.13.
How many shares outstanding does CellaVision AB have?
CellaVision AB has 23,851,547 shares outstanding.
What happened to CellaVision AB’s price movement after its last earnings report?
CellaVision AB reported an EPS of €0.123 in its last earnings report, beating expectations of €0.12. Following the earnings report the stock price went up 0.828%.
Which hedge fund is a major shareholder of CellaVision AB?
Currently, no hedge funds are holding shares in DE:C26
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CellaVision AB
CellaVision AB (publ), a Swedish enterprise established in 1994 and based in Lund, specializes in crafting and distributing advanced digital systems for analyzing blood and other bodily fluids within the healthcare industry. The company serves a global market, with operations extending across Sweden, the wider European continent, the Middle East, Africa, the Americas, and the Asia Pacific region. Their core product line includes automated digital imaging devices such as the CellaVision DM1200 and DM9600, engineered to automatically capture detailed digital images of cells from blood smears and fluid preparations. Additionally, they offer the CellaVision DC-1 analyzer. Beyond hardware, CellaVision provides a suite of specialized software applications. The CellaVision Peripheral Blood Application streamlines and standardizes the morphological assessment of peripheral blood smears, while the CellaVision Advanced RBC Application facilitates a thorough examination of red blood cell morphology. For other body fluids, the CellaVision Body Fluid Application automates and standardizes their morphological evaluation. To enhance operational flexibility, the CellaVision Remote Review Software allows for the review of digital smears without geographical restrictions. Furthermore, the company delivers tools designed for laboratory management and educational purposes. The CellaVision Server Software integrates workflows across single or multiple testing facilities into a cohesive system. The CellaVision Dashboard provides an instant, visual summary of analyzer and reviewer performance data. The cloud-based CellaVision Proficiency Software assists laboratory managers in evaluating, tracking, and developing staff competency in cell morphology. For training and reference, the CellaVision CellAtlas features concise educational modules alongside a comprehensive cell image library. CellaVision also caters to the animal health sector with CellaVision VET, offering digital microscopy solutions for veterinary hematology. These innovative solutions are primarily supplied to hospitals and commercial laboratories worldwide.
C26 Company Deck
C26 Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented a generally positive operational and commercial picture: solid top-line growth (4.5% YoY; ~6% organic), record Americas performance (+≈59% in Americas sales), healthy margins (70% gross margin; 27% EBITDA margin) and progress on strategic initiatives (Bone Marrow launch, FDA 510(k) process, FPM development). Offsetting risks include APAC weakness (notably China), a distributor inventory adjustment in EMEA that depressed near-term sales, increased working capital leading to a negative total cash flow for the quarter, one-time CEO transition costs (SEK 9m) and temporary operational disruptions (SEK 2m delayed reagents). On balance, the positives — strong regional recovery in the Americas, product/reagent momentum in key markets, continued R&D investment and a solid cash buffer — outweigh the transitory and region-specific headwinds.View all DE:C26 earnings summariesTechnical Analysis
BICO Group AB Class B
―
SciBase Holding AB
―
Bactiguard Holding AB
―
Sectra AB Class B
―
Acarix AB
―